AG
TSVT

Artal Group’s 2seventy bio TSVT Stock Holding History

Artal Group’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-750,000
Closed -$7.65M – 131
2023
Q1 		$7.65M Buy
+750,000
New +$8.57M 0.45% 49

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Artal Group's TSVT Position: Q2 2023 in Review

Artal Group sold out of 2seventy bio (TSVT) in Q2 2023, closing a stake of 750,000 shares — an estimated $7.65M sold.

Artal Group first reported a position in TSVT in Q1 2023 and held it in 1 quarter. The position peaked at $7.65M in Q1 2023. 149 funds tracked by Wall St. Rank hold TSVT as of Q2 2023.

  • Artal Group reported no remaining 2seventy bio position as of Q2 2023 after selling out during the quarter.
  • Artal Group sold 750,000 2seventy bio shares in Q2 2023, an estimated $7.65M.
  • Artal Group first reported a position in 2seventy bio in Q1 2023 and held it in 1 quarter.
  • Artal Group's 2seventy bio position peaked at $7.65M in Q1 2023.
  • 149 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.